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Abstract
Background: Severe hypertriglyceridemia (HTG) is one cause of acute pancreatitis, yet the level of plasma
triglycerides likely to be responsible for inducing pancreatitis has not been clearly defined.
Methods and Results: A retrospective cohort study was conducted on patients presenting non-acutely to the
Healthy Heart Program Lipid Clinic at St. Paul’s Hospital with a TG level > 20 mM (1772 mg/dl) between 1986 and
2007. Ninety-five patients with TG > 20 mM at the time of referral were identified, in who follow up data was
available for 84. Fifteen patients (15.8%), with a mean outpatient TG level of 38.1 mM, had a history of acute
pancreatitis. Among 91 additional patients with less severe HTG, none had a history of pancreatitis when TG were
between 10 and 20 mM. Among patients with TG > 20 mM on presentation, 8 (8.5%), with a mean TG level of
67.8 mM, exhibited eruptive xanthomata. A diet high in carbohydrates and fats (79%) and obesity (47.6%) were the
two most frequent secondary causes of HTG at initial visit. By 2009, among patients with follow up data 53%
exhibited either pre-diabetes or overt Type 2 diabetes mellitus. Upon referral only 23 patients (24%) were receiving
a fibrate as either monotherapy or part of combination lipid-lowering therapy. Following initial assessment by a
lipid specialist this rose to 84%, and remained at 67% at the last follow up visit.
Conclusions: These results suggest hypertriglyceridemia is unlikely to be the primary cause of acute pancreatitis
unless TG levels are > 20 mM, that dysglycemia, a diet high in carbohydrates and fats, and obesity are the main
secondary causes of HTG, and that fibrates are frequently overlooked as the drug of first choice for severe HTG.
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Background
Hypertriglyceridemia (HTG), classically defined as fast-
ing plasma triacylglycerols (triglycerides, TG) > 2.3 mM
or 200 mg/dl, or 1.7 mM (150 mg/dl) in the definition
of metabolic syndrome [1], is a common laboratory
finding. Severe hypertriglyceridemia, e.g., TG > 20 mM
(1772 mg/dl), is much rarer and almost always caused
by a combination of inherited and secondary factors
[2,3]. Genetic disorders leading to hypertriglyceridemia
include familial combined hyperlipidemia, familial
hypertriglyceridemia, remnant removal disease (Type 3
dyslipidemia), deficiencies of lipoprotein lipase or apoli-
poprotein CII, and more recently characterized muta-
tions including variants of apolipoprotein A5 [4,5]. The
most common secondary contributors to severe hyper-
triglyceridemia include poorly controlled diabetes melli-
tus, obesity, high fat and simple carbohydrate diet,
excess alcohol consumption, hypothyroidism, and medi-
cations including thiazide diuretics, b-blockers, oral
estrogen, retinoids, and anti-retroviral agents [2,3].
Patients with severe HTG may present with classic
findings such as abdominal pain or overt pancreatitis,
eruptive or palmar xanthomas, lipemia retinalis, or they
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plication of severe HTG is acute pancreatitis, which may
lead to pancreatic necrosis and death [2,6]. The inci-
dence of classic signs and symptoms of HTG, including
pancreatitis, however, has not been determined in
patients presenting with severe HTG. In addition, the
level of plasma triglycerides at which acute pancreatitis
can be ascribed specifically to the presence of HTG has
not been reported.
The purpose of this study was to determine the fre-
quency of physical signs and symptoms of HTG includ-
ing pancreatitis among patients with severe HTG
referred to a specialty lipid disorders clinic over a 21-
year period. Specifically, our study attempted to deter-
mine: (a) the frequency of classical signs and symptoms
associated with severe HTG; (b) the most common sec-
ondary factors contributing to TG > 20 mM (1772 mg/
dl); (c) differences in treatment for severe HTG between
referring physicians and lipid clinic specialists; and (d)
changes in the lipid profile of patients with severe HTG
followed at a specialty lipid clinic. Overall, we found an
absence of pancreatitis unless TG were > 20 mM, a rela-
tively low incidence of classic clinical findings of HTG
such as eruptive xanthomas, the presence of diabetes or
pre-diabetes in the majority of HTG subjects, and a ten-
dency of non-lipid specialists to overutilize statins and
underutilize fibrates as their first-line treatment for
severe HTG.
Results
Patient Demographics (Table 1)
Between 1986 to 2007 the clinic saw a total of 95
patients with TG ≥ 20 mM at the time of first referral.
The mean age ± standard deviation was 54.2 ± 11.9
years, with 70 patients (73.7%) being male and 75
patients (78.9%) Caucasian.
History of Pancreatitis
Fifteen patients (15.8%) had a history of pancreatitis
p r i o rt or e f e r r a lt ot h ec l i n i c .O ft h e s e ,t h em e a nT G
level at the time of non-acute presentation to the clinic
was 38.13 mM [median 30.91 mM (IQ 25.6 - 52.2)],
with the lowest referral TG level associated with prior
pancreatitis being 20.5 mM (1815 mg/dl). Peak TG
levels at the time of acute pancreatitis were not available
for this analysis. Analysis of an additional cohort of 91
patients with TG levels between 10 and 20 mM (886 -
1771 mg/dl) at time of presentation to clinic revealed a
history of pancreatitis in only 3 patients. In these 3,
levels of TG at the time of acute pancreatitis were avail-
able, and all were > 20 mM (1771 mg/dl). As such, we
conclude that pancreatitis is unlikely to occur as a result
of hypertriglyceridemia unless TG are > 20 mM acutely.
Prevalence of dysglycemia (Table 2)
Thirty patients (31.6%) had a prior diagnosis of diabetes
mellitus (DM). Of these, HbA1 c levels were not routi-
nely available, however the majority (23/30) had poor
control, with a mean FBS of 9.97 ± 4.37 mM (179 ± 79
mg/dL) at presentation to the clinic, and only 11 were
on antihyperglycemic medication. An additional 5
patients (5.3%) were diagnosed with DM at their first
clinic visit. Four new diagnoses of DM were made dur-
ing the follow up period. In the entire group with severe
hyperTG, 39 patients (41.0%) had a diagnosis of Type 2
DM by 2009. An additional 11 patients (11.6%) had
impaired fasting glucose, giving a total of 50 patients
(52.6%) having impaired glucose metabolism. At the lat-
est visit, 82% of patients with a diagnosis of DM were
taking antihyperglycemic medication.
Other risk factors for hypertriglyceridemia and personal/
family history of CVD (Table 3)
Dietary assessment by clinic dietitians was performed
using three day food records plus a nutrient frequency
questionnaire. Fat intake was considered high if >35%
and carbohydrate intake high if >55% of total calories
[7]. Seventy-five patients (78.9%) had a diet high in fat
and carbohydrates based on these criteria. Forty-two
patients (49.4%) had no regular exercise. Alcohol con-
sumption of >14 drinks/week or 7 - 14 drinks/week
were recorded in 11 (11.6%) and 8 (8.4%) patients,
respectively. Of the 15 (17.1%) patients previously diag-
nosed with hypothyroidism, 5 were inadequately
Table 1 Demographic Information for HTG Patients At
Initial Clinic Visit
n/N %
Mean Age (yrs) 54.2 +/- 11.9 95/95
Gender Male 70/95 73.7
Female 25/95 26.3
Ethnicity Caucasian 75/95 78.9
South Asian 12/95 12.6
Chinese 4/95 4.2
Other 4/95 4.2
Table 2 Frequency of Diabetes and Elevated Fasting
Blood Sugar (FBS) in HTG Clinic Patients
n/N %
At Initial Visit: Past DM Diagnosis 30/95 31.6
FBS > 7 mM 23/30 76.7
New DM Diagnosis 5/52 9.6
At Interim: New DM Diagnosis 4/60 6.8
At Latest Visit: Total DM 39/95 41.1
Impaired Fasting Glucose 11/95 11.6
Total with Dysglycemia 50/95 52.6
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No new diagnoses of hypothyroidism were made during
follow up of this cohort. Twenty-four patients (25.3%)
had smoked cigarettes within the past year. Sixteen
patients (16.9%) were on beta-blockers, 6 (6.4%) were on
estrogen therapy, 4 (4.3%) were on anti-retroviral ther-
apy, and 3 (3.2%) were on a thiazide diuretic. Twelve
patients (12.6%) had a personal history of coronary
artery disease and 5 (5.3%) of peripheral vascular dis-
ease. Forty-seven patients (49.5%) indicated a history of
premature vascular disease in first-degree relatives; only
15 (15.8%) were aware of other family members having
dyslipidemia; however, this information was unknown to
many patients.
Physical findings (Table 4)
Obesity, defined as a body-mass-index > 30 kg/m
2,w a s
present in 45 patients (47.4%), 57% of whom were pre-
viously diagnosed with diabetes. Overweight, as defined
by a body-mass-index of 25-30 kg/m
2 was present in an
additional 29.5%, with only 23% of the cohort having a
BMI less than 25 kg/m
2. Eight patients (8.5%) presented
with eruptive xanthomas, occurring with a range of TG
levels of 20.5 - 171.9 mM, and a mean TG level of 67.8
mM [median 51.2 mM (IQ 27.55 - 97.85)]. Of these 8
patients, 2 were also felt to have lipemia retinalis (the
only 2 of the entire cohort in whom this was noted,
occurring at TG levels of 25.6 and 54.3 mM), 5 were
obese, and 4 were diabetic. Three patients (3.2%) had
palmar xanthomas. Corneal arcus was observed in 24
patients (25.3%). Three patients had abdominal tender-
ness at the initial visit, one of whom had a previous his-
tory of pancreatitis, and 6 were noted to have
hepatomegaly.
Pre-Clinic and In-Clinic Treatment (Table 5)
At the initial visit 23 patients (24.2%) were taking a
fibrate, with 17 on fibrate monotherapy, 4 on fibrate-sta-
tin, 1 on fibrate-niacin, and 1 on fibrate-omega-3 fatty
acids (fish oil). Sixteen patients (16.8%) were referred
taking statin monotherapy. Fifty-two patients (54.7%)
were taking no hypolipidemic therapy, either due to lack
of initiation or a history of lipid therapy intolerance. All
patients received extensive dietary counseling and
encouraged to limit dietary fats and simple carbohy-
drates as well as alcohol consumption. After the initial
visit 80 patients (84.2%) were taking fibrate therapy,
with 54 (56.8%) on fibrate monotherapy, 16 (16.8%) in
combination with fish oil, 9 (9.5%) in combination with
a statin, and 1 on fibrate-niacin combination. Eight
patients (8.4%) were placed on fish oil monotherapy,
while one was left on statin monotherapy. At the last
visit recorded (84 patients), 56 patients (66.7%)
remained on fibrate therapy, with 31 patients (36.9%) on
monotherapy, 11 (13.1%) in combination with a statin, 4
(4.8%) in combination with fish oil, and 1 in combina-
tion with niacin. Six patients (7.1%) were on statin
monotherapy, 3 (3.6%) on fish oil monotherapy, and 2
(2.4%) on niacin monotherapy. Of the remaining 25
patients, 17 (20.2%) were on combination therapy with-
out a fibrate, and 8 (9.5%) were on no treatment.
Table 3 Frequency of Risk Factors in HTG Patients at
Initial Clinic Visit
n/N %
High fat/sugar diet: 75/95 79
Physical Exercise: >5/wk 13/85 15.3
3-5/wk 15/85 17.6
< 3/wk 15/85 17.6
none 42/85 49.4
Alcohol Consumption: >14 drinks/wk 11/95 11.6
7-14 drinks/wk 8/95 8.4
1-7 drinks/wk 33/95 34.7
none 43/95 45.3
Diagnosed Hypothyroidism: 15/95 17.1
with TSH>5 5/15 33.3
Currently Smoking: 24/95 25.3
Medications: B-blocker 16/95 16.9
Estrogen 6/95 6.4
Anti-retrovirals 4/95 4.3
Thiazide diuretic 3/95 3.2
Personal History: Premature CAD 12/95 12.6
PVD 5/95 5.3
Family History: Premature CVD 47/95 49.5
Dyslipidemia 15/95 15.8
CAD = Coronary Artery Disease; PVD = Peripheral Vascular Disease;
CVD = Cardiovascular Disease; TSH = Thyroid Stimulating Hormone
Table 4 Frequency of Clinical Findings in HTG Patients
n/N %
Body Mass Index: > 30 kg/m2 45/95 47.4
25-30 kg/m2 28/95 29.5
< 25 kg/m2 22/95 23.2
Dermatological: Eruptive Xanthomas 8/95 8.5
Palmar Xanthomas 3/95 3.2
Ophthamalogical: Corneal Arcus 24/95 25.3
Lipemia Retinalis 2/95 2.1
Gastrointestinal: Abdominal tenderness 3/95 3.2
Hepatomegaly 6/95 6.3
Sandhu et al. Lipids in Health and Disease 2011, 10:157
http://www.lipidworld.com/content/10/1/157
Page 3 of 7Laboratory and Anthropometric Values of Patients from
Initial to Latest Visit (Table 6)
Triglyceride levels decreased from a mean of 35.04 ±
21.89 mM (3104 ± 1939 mg/dl) at the initial visit to
8.07 ± 8.71 mM (715 ± 772 mg/dl) at the latest visit
(Figure 1). Total cholesterol (TC) dropped from 12.8 ±
6.37 mM (495 ± 247 mg/dl) to 6.72 ± 2.73 mM (260 ±
106 mg/dl), and TC to high density lipoprotein choles-
terol (HDL-C) ratio from 22.7 ± 25.59 to 6.70 ± 3.19
(Figure 1). No statistically significant changes were
detected for HDL-C. Average BMI was unchanged from
first to the latest visit.
Discussion
Clinical findings in patients with severe HTG
The incidence of clinical findings including pancreatitis
and physical stigmata in patients with severe HTG have
not previously been documented. Other studies have
reported average acute levels of plasma TG in patients
with TG-induced pancreatitis of 51.8 mM [8] and 50.5
mM [9], but did not define a lower limit of plasma TG
at which HTG could be identified as the likely cause of
the pancreatitis. A key finding of this study is that acute
pancreatitis as a consequence of HTG occurs relatively
infrequently, and rarely if ever unless TG levels are
greater than 20 mM (1772 mg/dl). In this study a his-
tory of pancreatitis was present in 15.8% of individuals
referred with TG > 20 mM, occurring in patients with a
minimum non-acute TG level of 20.5 mM (1816 mg/dl)
and a mean non-acute TG level of 38.1 mM (3376 mg/
dl). Of 91 patients seen in our clinic with non-acute TG
levels between 10-20 mM, none had a history of pan-
creatitis unless their TG were > 20 mM acutely. Erup-
tive xanthomas were found in only 8.5% of patients, at a
minimum TG level of 20.5 mM (1816 mg/dl) and an
average TG level of 67.8 mM (6007 mg/dl), even higher
than that required to induce pancreatitis. However, the
level of TG did not accurately predict whether patients
would develop these signs. For instance, pancreatitis was
observed in 2 patients with TG levels of 20-21 mM, and
only in 1 out of 5 patients who had TG>70 mM. It is
likely that factors other than the TG level may contri-
bute to the development of pancreatitis and other physi-
cal characteristics observed in HTG patients. Further
studies with a greater sample size and possibly knowl-
edge of the underlying genetic traits are needed to bet-
ter elucidate such relationships. Lipemia retinalis was an
infrequent finding in our study. While it was uncertain
whether this was assessed at the time of non-acute pre-
sentation in all patients, it appears that this finding is
present mainly in very severe HTG and more likely to
be seen in the acute versus non-acute HTG setting.
Chylomicronemia syndrome, defined as TG > 1000
mg/dl (11.3 mM) plus one of either eruptive xanthomas,
lipemia retinalis, or abdominal pain/pancreatitis, had a
previously quoted incidence rate of 1.7/10000 patients
Table 5 Prevalence of Lipid-lowering Medications in Clinic HTG Patients
Upon Arrival* Clinic Treatment* Latest Visit**
n (%) n (%) n (%)
Monotherapy: Fibrate 17 (17.9) 54 (56.8) 31 (36.9)
Statin 16 (16.8) 1 (1.1) 6 (7.1)
Fish Oil 1 (1.1) 8 (8.4) 3 (3.6)
Niacin 1 (1.1) 0 2 (2.4)
Resin 1 (1.1) 0 1 (1.2)
Combination: Fibrate/Statin 4 (4.2) 9 (9.5) 11 (13.1)
Fibrate/Niacin/Fish Oil 1 (1.1) 1 (1.1) 1 (1.2)
Fibrate/Fish Oil 1 (1.1) 16 (16.8) 4 (4.8)
Other 0 2 (2.2) 17 (20.2)
* N = 95, ** N = 84
Table 6 Laboratory Values and Anthropometry of HTG Patients from Initial to Latest Visit
Initial Visit (mM) Latest Visit (mM) Paired t - test
Laboratory: Triglycerides 35.04 ± 21.89 8.07 ± 8.7 p < 0.0001
TC 12.8 ± 6.37 6.72 ± 2.73 p < 0.0001
TC/HDL-C 22.7 ± 25.59 6.70 ± 3.19 p < 0.0001
HDL-C 0.87 ± 1.05 1.05 ± 0.31 p = 0.224
Systolic BP 126.91 ± 18.12 128.11 ± 19.96 p = 0.634
Diastolic BP 80.46 ± 10.05 80.46 ± 10.05 p < 0.05
Anthropometric: BMI 29.61 ± 5.17 29.55 ± 6.27 p = 0.917
TC = Total Cholesterol; HDL-C = High Density Lipoprotein Cholesterol; BP = Blood Pressure; BMI = Body Mass Index
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rates, however, have led to a potential increase in this
incidence. In our high risk patient population, 23
patients (24.2%) met the criteria for this syndrome.
Secondary contributors to severe HTG
In addition to inherited causes of HTG that were
undoubtedly present in most if not all the patients in
this cohort, the most common secondary factors predis-
posing to HTG were a high fat and carbohydrate diet,
physical inactivity and obesity. In 53% of the cohort, and
concomitant with these other factors in many cases, dys-
glycemia was present in the form of pre-diabetes or
overt Type 2 diabetes mellitus. Two previous studies
found similarly high levels of diabetes, 72% [8] and 43%
[9], in acute HTG-induced pancreatitis. The negative
impact of metabolic syndrome, dysglycemia and abdom-
inal obesity on triglyceride levels is well documented
[1,3,11]. Insulin resistance and diabetes are associated
with an increase in plasma TG for multiple reasons,
including reduced insulin-dependent inhibition of lipoly-
sis in adipocytes, increased TG and VLDL production
by the liver, and impaired insulin-dependent activation
of lipoprotein lipase and hydrolysis of TG-rich lipopro-
teins [3,12].
Although known to contribute to HTG, the incidence
of uncontrolled DM and hypothyroidism has not been
well characterized in previous studies. The majority of
patients (77%) with DM at first presentation to the
clinic had poor glycemic control. Diagnosed hypothyr-
oidism was present in 17.1% of patients, with a signifi-
cant number of these (33.3%) having evidence of
inadequate thyroid hormone replacement (TSH > 5
uIU/mL). The high incidence of such comorbidities
highlights the importance of controlling these factors to
prevent severe HTG. All told, 100% of our patients had
at least one secondary factor contributing to their HTG.
Although genetic testing is not currently available for
Figure 1 Triglycerides, Total Cholesterol, and Total Cholesterol:HDL-C Ratio at Initial and Latest Clinic Visit in HTG Patients.* ,
significant difference between means, p < 0.001 (two tail; pair student t-test).
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available for many other inherited causes of HTG, our
assumption is that in most if not all of our patients a
combination of primary genetic plus secondary causes
contributed to their severe HTG. In any patient with
TG levels >3-4 mM, it should be assumed there is a
likely underlying inherited cause of HTG present, aggra-
vated further by one or more secondary factors.
Lipid Lowering Therapy
At initial visit, almost as many patients were being trea-
ted by their referring physician with statin monotherapy
as fibrate monotherapy, the recommended first line
treatment for severe HTG. Lipid specialists, on the
other hand, treated most patients with fibrate mono-
therapy. It has been well documented that fibrates are
the most efficacious first line pharmacotherapy for
HTG, and typically lower TG very rapidly and effectively
[3,11,13]. Adjuncts to this include lifestyle modifications,
such as following a low fat and low simple carbohydrate
diet, avoiding alcohol, control of blood sugars, and fish
oil Ω-3 fatty acid) supplementation [3,14]. Fish oil doses
of at least 2 g in doses divided two or three times daily
are needed to have any major TG-lowering effect, and
doses of up to 12 g daily can be used. Niacin (nicotinic
acid) is also a potent TG-lowering agent. It is not practi-
cal to use in the acute setting, however, where reducing
the risk of pancreatitis is the main priority, given the
time needed to titrate the niacin dose to therapeutic
levels (≥ 1000 mg daily). In most cases, apart from
homozygous lipoprotein lipase or apolipoprotein CII
deficiency, use of a fibrate in combination with a low fat
and carbohydrate diet and improvement in blood sugar
control is highly efficacious in reducing severe HTG to
more moderate levels, as seen in our cohort. While sta-
tins have some TG-lowering effect, ranging from 20 -
28% at higher doses of newer statins [15], they are not
effective enough in this regard to remove the risk of
pancreatitis in patients with severe HTG, and should
not be used on their own as first line agents. The discre-
pancy between treatments initiated by referring physi-
cians and lipid specialists needs to be addressed,
perhaps by an education series focused on lipid treat-
ment. By doing so, it is possible that more patients
would be able to achieve marked TG reduction without
lipid clinic referrals.
In patients with severe HTG and persistent elevation
of apolipoprotein B100 or LDL-C following initiation of
TG-lowering therapy, treatment with combined fibrate/
statin may be indicated. Although the recent ACCORD
Lipid trial did not find additional benefit of adding feno-
fibrate to a statin in terms of cardiovascular event rate
in patients with type 2 diabetes [16], it may be necessary
to continue fibrate therapy long term in severe HTG
patients who also require a statin, in order to maintain
TG levels out of the range of risk for pancreatitis. While
we did not observe pancreatitis in anyone with TG
levels < 20 mM, due to the volatile nature of TG eleva-
tion when secondary factors are not well controlled, we
recommend attempting to lower TG levels to not more
than a maximum of 6-8 mM in order to reduce the risk
of TG rising into pancreatitis range acutely.
Conclusions
This is the first cohort in which incidence rates of clini-
cal findings in patients with severe HTG have been
quantified. The classic findings of pancreatitis and erup-
tive xanthomas occurred in a relatively small percentage
of patients, and not unless TG were > 20 mM (1772
mg/dl). Patients with extreme HTG have a combination
of primary and secondary factors contributing to their
HTG. Lifestyle changes (low fat and simple carbohydrate
diet, increased exercise) and a reduction in comorbid-
ities (uncontrolled DM and hypothyroidism) are critical
aspects of managing HTG in conjunction with pharma-
cotherapy using fibrates and omega-3 fatty acid supple-
ments. Fibrates remain the treatment of choice for
severe HTG, with statins lacking sufficient TG-lowering
effect to remove the risk of pancreatitis.
Methods
A retrospective chart review was conducted in the
Healthy Heart Program Lipid (now Prevention) Clinic at
St. Paul’s Hospital, Vancouver, Canada. Patients seen in
the clinic between the years of 1986 and 2007 with
plasma triglyceride levels greater than 20 mM upon
referral were included in the study. Patients were identi-
fied either by individual chart review, or after 1999 by
scan of an electronic clinic database. In total, 95 patients
met this inclusion criterion; of those, 84 patients
returned for at least one follow up visit, and many
patients have been followed intermittently for several
years. Data extracted from the chart from the patient’s
initial visit and most recent follow up visit for the cur-
rent study included: demographics (age, gender, ethnic
background); history of pancreatitis; presence of
increased fasting glucose or diagnosis of diabetes at
initial or follow up visit; other historical features includ-
ing secondary factors potentially contributing to the pre-
sence of HTG (dietary carbohydrates and fats, level of
physical activity, alcohol consumption, hypothyroidism,
current smoking, and medications potentially raising TG
including thiazide diuretics, b-blockers, oral estrogen,
and anti-retroviral agents), history of cardiovascular dis-
ease, and family history of premature vascular disease or
known dyslipidemia; physical findings including body
mass index, dermatologic findings including eruptive or
palmar xanthomas, eye findings including corneal arcus
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epigastric tenderness and hepatomegaly. Use of lipid-
lowering therapies including fibrates (gemfibrozil or
fenofibrate), statins (simvastatin, pravastatin, atorvastatin
or rosuvastatin), niacin, omega-3 fatty acids (fish oils),
and bile acid binding resins were recorded. Total choles-
terol, triglyceride levels, HDL-cholesterol (HDL-C) and
total cholesterol:HDL-C ratio were recorded for the
initial and follow up visits. This study was approved by
the Institutional Ethics Review Board for Human Stu-
dies, Providence Health Care Research Institute, Van-
couver, BC, Canada.
Statistical Analysis
The cohort’s characteristics were expressed as mean and
standard deviation for continuous variables. Frequency
of findings was used for dichotomous traits. Means were
compared using a paired Students t test, when normality
was confirmed, two tailed - 95% CI with a p value <
0.05 considered statistically significant. Data analysis was
performed using SPSS v12.0 (SPSS Inc., Chicago, IL).
Acknowledgements
This study was funded by a Faculty of Medicine Summer Studentship Award
to SS, and by CIHR operating grant MOP-12660 to GAF.
Author details
1Department of Medicine, Healthy Heart Program Prevention Clinic, UBC
James Hogg Research Centre, Providence Heart + Lung Institute, St. Paul’s
Hospital, University of British Columbia, 1081 Burrard St., Vancouver, BC V6Z
1Y6 Canada.
2Department of Pathology and Laboratory Medicine, Healthy
Heart Program Prevention Clinic, UBC James Hogg Research Centre,
Providence Heart + Lung Institute, St. Paul’s Hospital, University of British
Columbia, 1081 Burrard St., Vancouver, BC V6Z 1Y6 Canada.
Authors’ contributions
SS participated in the collection and analysis of data and writing of the
manuscript. AA-S and CT participated in the data collection and analysis. JF
participated in conception of the study, supervision, data analysis and
manuscript editing. GF participated in conception and oversight of the
study, supervision, data analysis and manuscript preparation. All authors read
and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 July 2011 Accepted: 11 September 2011
Published: 11 September 2011
References
1. Alberti KG, Zimmet P, Shaw J: The metabolic syndrome–a new worldwide
definition. Lancet 2005, 366:1059-1062.
2. Brunzell JD, Deeb SS: Familial lipoprotein lipase deficiency, apo CII
deficiency and hepatic lipase deficiency. In The Metabolic and Molecular
Bases of Inherited Disease.. 8 edition. Edited by: Scriver CR, Beaudet AL, Sly
WS, Valle D. New York: McGraw-Hill; 2001:2789-2816.
3. Yuan G, Al-Shali KZ, Hegele RA: Hypertriglyceridemia: its etiology, effects
and treatment. CMAJ 2007, 176:1113-1120.
4. Wang J, Ban MR, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL,
Hegele RA: APOA5 genetic variants are markers for classic
hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin
Pract Cardiovasc Med 2008, 5:730-737.
5. Johansen CT, Wang J, Lanktree MB, Cao H, McIntyre AD, Ban MR,
Martins RA, Kennedy BA, Hassell RG, Visser ME, et al: Excess of rare variants
in genes identified by genome-wide association study of
hypertriglyceridemia. Nat Genet 2010, 42:684-687.
6. Truninger K, Schmid PA, Hoffmann MM, Bertschinger P, Ammann RW:
Recurrent acute and chronic pancreatitis in two brothers with familial
chylomicronemia syndrome. Pancreas 2006, 32:215-219.
7. Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, And
Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel
III). JAMA 2001, 285:2486-2497.
8. Fortson MR, Freedman SN, Webster PD: Clinical assessment of
hyperlipidemic pancreatitis. Am J Gastroenterol 1995, 90:2134-2139.
9. Lloret Linares C, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-
Rousselot D, Levy P, Ruszniewski P, Bruckert E: Acute pancreatitis in a
cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas
2008, 37:13-12.
10. Leaf DA: Chylomicronemia and the chylomicronemia syndrome: a
practical approach to management. Am J Med 2008, 121:10-12.
11. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular S:
Canadian Cardiovascular Society position statement–recommendations
for the diagnosis and treatment of dyslipidemia and prevention of
cardiovascular disease. Can J Cardiol 2006, 22:913-927.
12. Verges BL: Dyslipidaemia in diabetes mellitus. Review of the main
lipoprotein abnormalities and their consequences on the development
of atherogenesis. Diabetes Metab 1999, 25(Suppl 3):32-40.
13. Barter PJ, Rye KA: Cardioprotective properties of fibrates: which fibrate,
which patients, what mechanism? Circulation 2006, 113:1553-1555.
14. Oh R: Practical applications of fish oil (Omega-3 fatty acids) in primary
care. J Am Board Fam Pract 2005, 18:28-36.
15. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA,
Blasetto JW: Comparison of the efficacy and safety of rosuvastatin versus
atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Am J Cardiol 2003, 92:152-160.
16. Ginsberg HN, Elam MB, Lovato LC, Crouse JR, Leiter LA, Linz P,
Friedewald WT, Buse JB, Gerstein HC, Probstfield J, et al: Effects of
combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010,
362:1563-1574.
doi:10.1186/1476-511X-10-157
Cite this article as: Sandhu et al.: Incidence of pancreatitis, secondary
causes, and treatment of patients referred to a specialty lipid clinic with
severe hypertriglyceridemia: a retrospective cohort study. Lipids in
Health and Disease 2011 10:157.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sandhu et al. Lipids in Health and Disease 2011, 10:157
http://www.lipidworld.com/content/10/1/157
Page 7 of 7